Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule

In February 2015, a nine-valent human papillomavirus vaccine (HPV9) was authorized for use in Canada. The purpose of this statement is to summarize information on this vaccine and to provide evidence-based recommendations on its use in the context of recommendations for all HPV vaccines currently authorized for use in Canada. In addition, this statement will clarify minimum intervals between doses of HPV vaccines for two-dose and three-dose HPV immunization schedules.